Your browser doesn't support javascript.
loading
MicroRNA delivery systems in glioma therapy and perspectives: A systematic review.
Jiménez-Morales, José Marcos; Hernández-Cuenca, Yanet Elisa; Reyes-Abrahantes, Ander; Ruiz-García, Henry; Barajas-Olmos, Francisco; García-Ortiz, Humberto; Orozco, Lorena; Quiñones-Hinojosa, Alfredo; Reyes-González, Jesús; Abrahantes-Pérez, María Del Carmen.
Afiliação
  • Jiménez-Morales JM; Precision Translational Oncology Laboratory, National Institute of Genomic Medicine (INMEGEN), 14610 Mexico City, Mexico.
  • Hernández-Cuenca YE; Precision Translational Oncology Laboratory, National Institute of Genomic Medicine (INMEGEN), 14610 Mexico City, Mexico.
  • Reyes-Abrahantes A; Precision Translational Oncology Laboratory, National Institute of Genomic Medicine (INMEGEN), 14610 Mexico City, Mexico.
  • Ruiz-García H; Department of Neurosurgery, Mayo Clinic, Jacksonville, United States; Brain Tumor Stem Cell Research Laboratory, Mayo Clinic, Jacksonville, United States.
  • Barajas-Olmos F; Immunogenomics and Metabolic Diseases Laboratory, National Institute of Genomic Medicine (INMEGEN), 14610 Mexico City, Mexico.
  • García-Ortiz H; Immunogenomics and Metabolic Diseases Laboratory, National Institute of Genomic Medicine (INMEGEN), 14610 Mexico City, Mexico.
  • Orozco L; Immunogenomics and Metabolic Diseases Laboratory, National Institute of Genomic Medicine (INMEGEN), 14610 Mexico City, Mexico.
  • Quiñones-Hinojosa A; Department of Neurosurgery, Mayo Clinic, Jacksonville, United States; Brain Tumor Stem Cell Research Laboratory, Mayo Clinic, Jacksonville, United States.
  • Reyes-González J; Precision Translational Oncology Laboratory, National Institute of Genomic Medicine (INMEGEN), 14610 Mexico City, Mexico. Electronic address: jreyes2702@gmail.com.
  • Abrahantes-Pérez MDC; Precision Translational Oncology Laboratory, National Institute of Genomic Medicine (INMEGEN), 14610 Mexico City, Mexico. Electronic address: mcabrahantes@inmegen.gob.mx.
J Control Release ; 349: 712-730, 2022 09.
Article em En | MEDLINE | ID: mdl-35905783
ABSTRACT
Gliomas are the deadliest of all primary brain tumors, and they constitute a serious global health problem. MicroRNAs (miRNAs) are gene expression regulators associated with glioma pathogenesis. Thus, miRNAs represent potential therapeutic agents for treating gliomas. However, miRNAs have not been established as part of the regular clinical armamentarium. This systemic review evaluates current molecular and pre-clinical studies with the aim of defining the most appealing supramolecular platform for administering therapeutic miRNA to patients with gliomas. An integrated analysis suggested that cationic lipid nanoparticles, functionalized with octa-arginine peptides, represent a potentially specific, practical, non-invasive intervention for treating gliomas. This supramolecular platform allows loading both hydrophilic (miRNA) and hydrophobic (anti-tumor drugs, like temozolomide) molecules. This systemic review is the first to describe miRNA delivery systems targeted to gliomas that integrate several types of molecules as active ingredients. Further experimental validation is warranted to confirm the practical value of miRNA delivery systems.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / MicroRNAs / Glioma Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / MicroRNAs / Glioma Idioma: En Ano de publicação: 2022 Tipo de documento: Article